Narrow search
Showing 1 - 10 of 55,659
Cover Image
Medical Technology : Electromedicine Driving Healthcare
Heng, Stefan - 2015
Innovative products form the foundation for the international success of electromedical technology in Germany. This is shown both in the strong sales achieved by the German medical technology segment compared with other industrial countries and the export share of more than 70%, which even...
Persistent link: https://www.econbiz.de/10013015990
Cover Image
Trade in Medicines
Abbott, Frederick M. - 2016
, distribution and trade in pharmaceuticals and related supplies are subject to government regulatory control at a number of levels … differential regulation may unnecessarily hinder the cross-border movement of pharmaceuticals, particularly among regions that … include chapters covering intellectual property rights and regulatory data with respect to pharmaceuticals, as well as …
Persistent link: https://www.econbiz.de/10014133283
Cover Image
Access to Medicines in India : A Review of Recent Concerns
Park, Chan - 2015
(Amendment) Act of 2005, which introduced product patent protection for pharmaceuticals for the first time since 1972. Although …
Persistent link: https://www.econbiz.de/10013039410
Cover Image
Shortages of medicines in OECD countries
Chapman, Suzannah - 2022
Even in wealthy economies, access to medicines is increasingly affected by medicine shortages – an issue exacerbated with the onset of the COVID-19 pandemic. The aim of this paper was to examine the extent and nature of medicine shortages in OECD countries (pre-COVID-19) and explore the...
Persistent link: https://www.econbiz.de/10013174584
Cover Image
Medical Research on Pharmaceutical Marketing : Is a Bias Ever Just a Bias?
Rubin, Paul H. - 2003
The literature written by physicians about pharmaceutical marketing and promotion generally views this activity as harmful. This harm supposedly occurs because physicians who have contact with pharmaceutical sales representatives sometimes change their prescribing behavior. However, this result...
Persistent link: https://www.econbiz.de/10014075862
Cover Image
Valuing Medical Innovation
Hemel, Daniel J.; Ouellette, Lisa Larrimore - 2022
Scholars and policymakers across the ideological spectrum agree that the U.S. drug pricing system is deeply flawed. Most reform proposals focus on one symptom: high prices for existing drugs. But high prices aren’t all that ails the U.S. drug pricing system: Current law also provides weak...
Persistent link: https://www.econbiz.de/10014078244
Cover Image
The Cost of Imbalance in Clinical Trials
Chassang, Sylvain; Feng, Rong - National Bureau of Economic Research - 2022
Clinical trials following the "gold standard" of random assignment frequently use independent lotteries to allocate patients to treatment and control arms. However, independent assignment can generate treatment and control arms that are unbalanced (i.e. treatment and control populations with...
Persistent link: https://www.econbiz.de/10013477237
Cover Image
On the rise of health spending and longevity
Fonseca, Raquel; Michaud, Pierre-Carl; Galama, Titus; … - 2009
We use a calibrated stochastic life-cycle model of endogenous health spending, asset accumulation and retirement to investigate the causes behind the increase in health spending and life expectancy over the period 1965-2005. We estimate that technological change along with the increase in the...
Persistent link: https://www.econbiz.de/10003925549
Cover Image
Medical innovations and ageing : a health economics perspective
Grossmann, Volker - 2021
surveys empirical evidence on medical R&D incentives, R&D costs of pharmaceuticals, and the cost-effectiveness of health …
Persistent link: https://www.econbiz.de/10012653346
Cover Image
Medical Provisions Post-Brexit
Hewson, Victoria - 2021
There are three main factors behind the fears in relation to medical provisions post-Brexit. Here we examine what the potential problems are and the available solutions. The flexibility available to the UK government and regulators means that they should be able to overcome the regulatory...
Persistent link: https://www.econbiz.de/10013224824